Half‐Life Extension through HESylation®

[1]  C. Won,et al.  PEG-modified biopharmaceuticals , 2009 .

[2]  J. Kressler,et al.  Enzymatically catalyzed HES conjugation using microbial transglutaminase: Proof of feasibility. , 2009, Journal of pharmaceutical sciences.

[3]  D. Spahn,et al.  Repetitive Large-Dose Infusion of the Novel Hydroxyethyl Starch 130/0.4 in Patients with Severe Head Injury , 2003, Anesthesia and analgesia.

[4]  H. Taegtmeyer,et al.  Synthesis of polymer-bound hemoglobin samples , 1981 .

[5]  W. Jurecka,et al.  Human monocytes and keratinocytes in culture ingest hydroxyethylstarch , 2005, Archives of Dermatological Research.

[6]  R. Whaley,et al.  Pegademase Bovine: Replacement Therapy for Severe Combined Immunodeficiency Disease , 1991, DICP : the annals of pharmacotherapy.

[7]  D. Cook,et al.  Resuscitation fluid use in critically ill adults: an international cross-sectional study in 391 intensive care units , 2010, Critical care.

[8]  Herbert J Meiselman,et al.  Antibody against poly(ethylene glycol) adversely affects PEG‐asparaginase therapy in acute lymphoblastic leukemia patients , 2007, Cancer.

[9]  M. Westphal,et al.  Hydroxyethyl Starches: Different Products – Different Effects , 2009, Anesthesiology.

[10]  I. Macdougall.  Recent advances in erythropoietic agents in renal anemia. , 2006, Seminars in nephrology.

[11]  T. Luger,et al.  Differential storage of hydroxyethyl starch (HES) in the skin: an immunoelectron-microscopical long-term study , 2001, Cell and Tissue Research.

[12]  P. Taupin,et al.  PEG and PEG conjugates toxicity: towards an understanding of the toxicity of PEG and its relevance to PEGylated biologicals , 2009 .

[13]  Zhi-xin Xu,et al.  Rational design of a potent, long-lasting form of interferon: a 40 kDa branched polyethylene glycol-conjugated interferon alpha-2a for the treatment of hepatitis C. , 2001, Bioconjugate chemistry.

[14]  A. N. de Belder,et al.  Antibodies against hydroxyethylstarch produced in rabbits by immunization with a protein-hydroxyetylstarch conjugate. , 1976, International archives of allergy and applied immunology.

[15]  M. Eichner,et al.  Endothelial Accumulation of Hydroxyethyl Starch and Functional Consequences on Leukocyte-Endothelial Interactions , 2002, European Surgical Research.

[16]  F. Davis,et al.  Alteration of immunological properties of bovine serum albumin by covalent attachment of polyethylene glycol. , 1977, The Journal of biological chemistry.

[17]  W. Schimetta,et al.  Hydroxyethyl Starch Antibodies in Humans: Incidence and Clinical Relevance , 1998, Anesthesia and analgesia.

[18]  M. Laxenaire,et al.  Réactions anaphylactoïdes aux substituts colloïdaux du plasma : incidence, facteurs de risque, mécanismes. Enquête prospective multicentrique française , 1994 .

[19]  Francesco M Veronese,et al.  PEGylation, successful approach to drug delivery. , 2005, Drug discovery today.

[20]  Robert M. Stroud,et al.  Efficiency of signalling through cytokine receptors depends critically on receptor orientation , 1998, Nature.

[21]  Kapp,et al.  Decreased activity of acid α‐glucosidase in a patient with persistent periocular swelling after infusions of hydroxyethyl starch , 1998, The British journal of dermatology.

[22]  M. Jarsch,et al.  Comparative Erythropoietin Receptor Binding Kinetics of C.E.R.A. and Epoetin-β Determined by Surface Plasmon Resonance and Competition Binding Assay , 2007, Pharmacology.

[23]  J. Egrie,et al.  Development and characterization of novel erythropoiesis stimulating protein (NESP) , 2001, British Journal of Cancer.